Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Synergy with DNA Damaging AgentsOther Presentations at AACR Highlight Progress in SuperGen's Oncology-Focused Preclinical Pipeline
SAN FRANCISCO, October 25, 2007 /PRNewswire-FirstCall/ -- SuperGen Inc. , a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2007 AACR-NCI-EORTC International Conference that MP470, its clinical-stage multi-targeted tyrosine kinase inhibitor, demonstrates preclinical synergy with DNA damaging agents (Poster A173).
Copies of the poster presentations will be available in the pipeline section of SuperGen's Web site: www.supergen.com.
Poster A173 (Abstract No. 1026)
MP470 Suppresses Repair of Double-Strand Breaks Following Treatment with DNA-damaging Agents
MP470, a multi-targeted tyrosine kinase inhibitor, demonstrated synergy with DNA damaging agents, including platinum based treatments, topoisomerase inhibitors, nucleoside analogs and the targeted agent erlotinib. Evidence presented here suggests that MP470 inhibits DNA damage repair through suppression of a critical DNA repair protein, Rad51.
"These pre-clinical studies with MP470 support our clinical development plan of MP470 in combination with well established chemotherapy regimens. DNA repair plays an important role in chemotherapy drug resistance, and MP470 has the potential to enhance the activity of these regimens. Based on this data, as well as its favorable pre-clinical toxicology profile, we are excited to advance MP470 into combination trials later this year," said Dr. Greg Berk, SuperGen's Chief Medical Officer.
MP470 is currently being evaluated in a phase 1 single agent clinical trial at two sites and will begin a phase 1b combination clinical trial with multiple chemotherapy regimens later this year.
Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.
Contacts Timothy L. Enns Mary M. Vegh SuperGen, Inc. SuperGen, Inc. SVP, Corporate Communications Manager, Investor Relations & Business Development Tel: (925) 560-2845 Tel: (925) 560-0100 E-mail: E-mail:firstname.lastname@example.org email@example.com
CONTACT: Timothy L. Enns, SVP, Corporate Communications & BusinessDevelopment, +1-925-560-0100, , or Mary M. Vegh, Manager,Investor Relations, +1-925-560-2845, , both ofSuperGen, Inc. firstname.lastname@example.org email@example.com
Web site: http://www.supergen.com/
Ticker Symbol: (NASDAQ-NMS:SUPG)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: October 2007